# OnCo record paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026" ;
  schema:name "Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial"@en ;
  schema:description "The 812-patient trial in which adding the AKT inhibitor capivasertib to first-line paclitaxel did not lengthen life in metastatic triple-negative breast cancer (17.7 versus 18.0 months), even in the 31 percent of patients whose tumours carried the pathway alterations it targets."@en ;
  schema:url <https://onco.cc/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.annonc.2025.12.012>, <https://pubmed.ncbi.nlm.nih.gov/41422862/>, <https://clinicaltrials.gov/study/NCT03997123> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1016/j.annonc.2025.12.012> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Schmid P, McArthur HL, Cortés J, et al." ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:targets <https://onco.cc/targets/akt/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/> ;
  onco:trials <https://onco.cc/trials/nct03997123/> ;
  onco:people <https://onco.cc/people/peter-schmid/>, <https://onco.cc/people/javier-cortes/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .